CBD: research and patient questions (Page 4)

Consider the use of oral cannabinoids as a potential treatment option for patients with insomnia, while monitoring for individual responses and side effects.

This pilot study indicates that medicinal cannabis may be a feasible treatment option for adolescents with Tourette Syndrome, warranting further investigation in a fully powered trial.

While purified CBD is generally well-tolerated in clinical trials, the widespread availability of unregulated CBD-infused foods presents safety risks due to unpredictable dosing, lack of extract standardization, and pronounced increases in bioavailability when consumed with dietary fats. Integrative clinicians should counsel patients on the variability and lack of federal safety oversight in commercial CBD food products, keeping potential drug-drug interactions and elevated liver enzyme risks in mind.

While cannabidiol (CBD) demonstrates a favorable safety profile and preliminary signals of efficacy in psychosis and anxiety, there is currently inadequate high-quality evidence to support its use for any psychiatric disorder. Clinicians must advise patients regarding the lack of product regulation, potential for significant CYP450 drug-drug interactions (especially affecting liver transaminases), and the risk of unlabelled THC contamination in commercial formulations.

Clinicians should consider the varying levels of evidence regarding the efficacy and safety of cannabis and cannabinoids when making treatment decisions. Systematic reviews can provide valuable insights into the credibility of these associations.

While observational studies and one RCT suggest modest behavioral and social communication benefits from full-spectrum, high-CBD-to-THC cannabis extracts in pediatric autism spectrum disorder, current robust trial data do not support generalized routine use. Cannabinoids should be reserved as an adjunctive therapeutic option under strict specialist medical supervision, carefully weighing the modest potential benefits against the neurodevelopmental and cognitive risks of pediatric THC exposure.

Current clinical evidence regarding the use of cannabinoids for postoperative pain in orthopedic surgery remains inconclusive due to significant trial heterogeneity and lack of product standardization. While THC/CBD combinations demonstrate modest potential for opioid-sparing effects and CBD shows early short-term promise, clinicians should exercise caution, carefully screen for concurrent substance use, and await standardized prospective trials before implementing routine perioperative cannabinoid protocols.

Clinicians should be cautious when recommending low-dose CBD products, as the evidence for their effects is still inconclusive.

A short randomised trial of a high-CBD, low-THC oral extract in 61 people with Parkinson's disease, a group who use cannabis often despite thin evidence.

A double-blind trial testing whether a CBD-rich extract taken before a root canal reduced anxiety during the procedure or pain afterwards.